ArticleJournal of menopausal medicine2025
Distinguishing Polycystic Ovary Syndrome Phenotype D from Functional Hypothalamic Amenorrhea with Polycystic Ovarian Morphology: Clinical and Hormonal Insights from a Pilot Retrospective Study.
Article in Journal of menopausal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesThis study was conducted to compare the clinical and hormonal characteristics among women with polycystic ovary syndrome (PCOS) phenotype D, functional hypothalamic amenorrhea (FHA) with polycystic ovarian morphology (PCOM), and FHA without PCOM and investigate potential markers for their distinction.
methodsThis retrospective pilot study included women who were examined for menstrual irregularities at a Korean tertiary hospital during 2018-2025 with following conditions: PCOS-D (n = 66), FHA with PCOM (n = 10), and FHA without PCOM (n = 29). Clinical features and hormonal profiles were analyzed using nonparametric tests, effect size estimation, and logistic regression.
resultsBMI, along with LH, FSH, and AMH levels differed significantly across groups. AMH levels exhibited the following gradient: highest in PCOS, intermediate in FHA-PCOM, and lowest in FHA without PCOM. Subgroup analysis indicated that LH and FSH levels alongside LH/FSH ratio distinguished PCOS-D from FHA-PCOM (all
conclusionLH/FSH ratio, supported by BMI and clinical history, may help distinguish PCOS-D from FHA-PCOM. FHA-PCOM represents a distinct but understudied subgroup. These results are preliminary and require validation through larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.